Research ExplorerPublicationsPembrolizumab outperforms tyrosine kinase inhibitors as adju...

Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy

Standard

Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy. / Laukhtina, Ekaterina; Quhal, Fahad; Mori, Keiichiro; Sari Motlagh, Reza; Rajwa, Pawel; Yanagisawa, Takafumi; Mostafaei, Hadi; König, Frederik; Aydh, Abdulmajeed; Pradere, Benjamin; Enikeev, Dmitry; Karakiewicz, Pierre I; Schmidinger, Manuela; Shariat, Shahrokh F.

In: EUR UROL ONCOL, Vol. 5, No. 1, 02.2022, p. 120-124.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Laukhtina, E, Quhal, F, Mori, K, Sari Motlagh, R, Rajwa, P, Yanagisawa, T, Mostafaei, H, König, F, Aydh, A, Pradere, B, Enikeev, D, Karakiewicz, PI, Schmidinger, M & Shariat, SF 2022, 'Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy', EUR UROL ONCOL, vol. 5, no. 1, pp. 120-124. https://doi.org/10.1016/j.euo.2021.12.007

APA

Laukhtina, E., Quhal, F., Mori, K., Sari Motlagh, R., Rajwa, P., Yanagisawa, T., Mostafaei, H., König, F., Aydh, A., Pradere, B., Enikeev, D., Karakiewicz, P. I., Schmidinger, M., & Shariat, S. F. (2022). Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy. EUR UROL ONCOL, 5(1), 120-124. https://doi.org/10.1016/j.euo.2021.12.007

Vancouver

Laukhtina E, Quhal F, Mori K, Sari Motlagh R, Rajwa P, Yanagisawa T et al. Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy. EUR UROL ONCOL. 2022 Feb;5(1):120-124. https://doi.org/10.1016/j.euo.2021.12.007

Bibtex

@article{2bfb8a7e7d2a4e6c9e736987ff33c977,
title = "Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy",
abstract = "We determined the oncologic outcomes and safety profiles of adjuvant immune checkpoint inhibitors (ICIs) compared to adjuvant tyrosine kinase inhibitors (TKIs) in patients at high risk after nephrectomy for clinically nonmetastatic renal cell carcinoma (RCC). Network meta-analyses were conducted for disease-free survival (DFS), overall survival (OS), and adverse events (AEs) with placebo as the common comparator arm. Six trials (KEYNOTE-564, S-TRAC, ASSURE, PROTECT, ATLAS, and SORCE) were included in our analysis. Compared to placebo, both pembrolizumab (hazard ratio [HR] 0.68, 95% confidence interval [CI] 0.51-0.92) and pazopanib 800 mg (HR 0.69, 95% CI 0.49-0.97) were significantly associated with better DFS. Adjuvant pembrolizumab (HR 0.54, 95% CI 0.30-0.97) was significantly associated with better OS compared to TKIs (HR 0.93, 95% CI 0.83-1.04). Analysis of treatment ranking revealed that pembrolizumab was the best treatment with regard to both DFS and OS and had the lowest likelihood of any-grade and high-grade AEs in comparison to TKIs. The superior oncologic benefit of pembrolizumab and its better toxicity profile support it as the new standard of care in the adjuvant setting for nephrectomy patients at high risk of RCC relapse. PATIENT SUMMARY: For patients with kidney cancer at high risk of relapse after surgical removal of their kidney, postoperative therapy with the immune checkpoint inhibitor pembrolizumab offers the best risk/benefit ratio.",
author = "Ekaterina Laukhtina and Fahad Quhal and Keiichiro Mori and {Sari Motlagh}, Reza and Pawel Rajwa and Takafumi Yanagisawa and Hadi Mostafaei and Frederik K{\"o}nig and Abdulmajeed Aydh and Benjamin Pradere and Dmitry Enikeev and Karakiewicz, {Pierre I} and Manuela Schmidinger and Shariat, {Shahrokh F}",
note = "Copyright {\textcopyright} 2021. Published by Elsevier B.V.",
year = "2022",
month = feb,
doi = "10.1016/j.euo.2021.12.007",
language = "English",
volume = "5",
pages = "120--124",
journal = "EUR UROL ONCOL",
issn = "2588-9311",
publisher = "Elsevier",
number = "1",

}

RIS

TY - JOUR

T1 - Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy

AU - Laukhtina, Ekaterina

AU - Quhal, Fahad

AU - Mori, Keiichiro

AU - Sari Motlagh, Reza

AU - Rajwa, Pawel

AU - Yanagisawa, Takafumi

AU - Mostafaei, Hadi

AU - König, Frederik

AU - Aydh, Abdulmajeed

AU - Pradere, Benjamin

AU - Enikeev, Dmitry

AU - Karakiewicz, Pierre I

AU - Schmidinger, Manuela

AU - Shariat, Shahrokh F

N1 - Copyright © 2021. Published by Elsevier B.V.

PY - 2022/2

Y1 - 2022/2

N2 - We determined the oncologic outcomes and safety profiles of adjuvant immune checkpoint inhibitors (ICIs) compared to adjuvant tyrosine kinase inhibitors (TKIs) in patients at high risk after nephrectomy for clinically nonmetastatic renal cell carcinoma (RCC). Network meta-analyses were conducted for disease-free survival (DFS), overall survival (OS), and adverse events (AEs) with placebo as the common comparator arm. Six trials (KEYNOTE-564, S-TRAC, ASSURE, PROTECT, ATLAS, and SORCE) were included in our analysis. Compared to placebo, both pembrolizumab (hazard ratio [HR] 0.68, 95% confidence interval [CI] 0.51-0.92) and pazopanib 800 mg (HR 0.69, 95% CI 0.49-0.97) were significantly associated with better DFS. Adjuvant pembrolizumab (HR 0.54, 95% CI 0.30-0.97) was significantly associated with better OS compared to TKIs (HR 0.93, 95% CI 0.83-1.04). Analysis of treatment ranking revealed that pembrolizumab was the best treatment with regard to both DFS and OS and had the lowest likelihood of any-grade and high-grade AEs in comparison to TKIs. The superior oncologic benefit of pembrolizumab and its better toxicity profile support it as the new standard of care in the adjuvant setting for nephrectomy patients at high risk of RCC relapse. PATIENT SUMMARY: For patients with kidney cancer at high risk of relapse after surgical removal of their kidney, postoperative therapy with the immune checkpoint inhibitor pembrolizumab offers the best risk/benefit ratio.

AB - We determined the oncologic outcomes and safety profiles of adjuvant immune checkpoint inhibitors (ICIs) compared to adjuvant tyrosine kinase inhibitors (TKIs) in patients at high risk after nephrectomy for clinically nonmetastatic renal cell carcinoma (RCC). Network meta-analyses were conducted for disease-free survival (DFS), overall survival (OS), and adverse events (AEs) with placebo as the common comparator arm. Six trials (KEYNOTE-564, S-TRAC, ASSURE, PROTECT, ATLAS, and SORCE) were included in our analysis. Compared to placebo, both pembrolizumab (hazard ratio [HR] 0.68, 95% confidence interval [CI] 0.51-0.92) and pazopanib 800 mg (HR 0.69, 95% CI 0.49-0.97) were significantly associated with better DFS. Adjuvant pembrolizumab (HR 0.54, 95% CI 0.30-0.97) was significantly associated with better OS compared to TKIs (HR 0.93, 95% CI 0.83-1.04). Analysis of treatment ranking revealed that pembrolizumab was the best treatment with regard to both DFS and OS and had the lowest likelihood of any-grade and high-grade AEs in comparison to TKIs. The superior oncologic benefit of pembrolizumab and its better toxicity profile support it as the new standard of care in the adjuvant setting for nephrectomy patients at high risk of RCC relapse. PATIENT SUMMARY: For patients with kidney cancer at high risk of relapse after surgical removal of their kidney, postoperative therapy with the immune checkpoint inhibitor pembrolizumab offers the best risk/benefit ratio.

U2 - 10.1016/j.euo.2021.12.007

DO - 10.1016/j.euo.2021.12.007

M3 - SCORING: Journal article

C2 - 34992006

VL - 5

SP - 120

EP - 124

JO - EUR UROL ONCOL

JF - EUR UROL ONCOL

SN - 2588-9311

IS - 1

ER -